NRIXNurix Therapeutics, Inc.
$25.33+152% 1Y
$25.33
$9.8452 weeks$27.79
The financials
Nurix Therapeutics, Inc. by the numbers
Nurix Therapeutics, Inc. (NRIX) reported revenue of $673M in Q3 2026 (quarter ended Aug 31, 2026), up 8426% from the same quarter a year earlier. That came with net income of $550M (82% of revenue). For the full year FY2025, revenue was $84M (+54% year on year) and net income −$264M. Its largest product in Q1 2026 (quarter ended Feb 28, 2026) was License at $30M, 83% of the disclosed total, well ahead of Collaboration at 17%. The next results filing is expected around Jan 27, 2027, the same week as a year ago.
| Income statement | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Revenue | $673M | $7.9M | +8426% |
| Operating income | $559M | −$91M | to a profit |
| Net income | $550M | −$86M | to a profit |
| Diluted EPS | $4.73 | −$1.03 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| License | $30M | 83% |
| Collaboration | $6.3M | 17% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $9.0M (-75%)
Collaboration grew -36% year on yearLicense -100% year on year
Segment Latestquarter on quarteryear on year
- Collaboration$9.0M$9.0Mquarter on quarter +45%year on year -36%+45%-36%
- License$0.00$0.00quarter on quarter -100%year on year -100%-100%-100%